Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| A1c | Glycated hemoglobin (hemoglobin A1c) |
| AACE | American Association of Clinical Endocrinology |
| ABCD | Adiposity-based chronic disease |
| ACC | American College of Cardiology |
| ACOFP | American College of Osteopathic Family Physicians |
| ADA | American Diabetes Association |
| AE | Adverse event |
| AESI | Adverse event of special interest |
| AF | Atrial fibrillation |
| AGA | American Gastroenterological Association |
| AHA | American Heart Association |
| AHFS | American Hospital Formulary Service |
| AHI | Apnea-hypopnea index |
| ALT | Alanine aminotransferase |
| ANCOVA | Analysis of covariance |
| AOM | Anti-obesity medication |
| API | Active pharmaceutical ingredient |
| ASCVD | Atherosclerotic cardiovascular disease |
| ASMBS | American Society for Metabolic and Bariatric Surgery |
| AST | Aspartate aminotransferase |
| AUC | Area under the concentration-time curve |
| AWP | Average wholesale price |
| BL | Baseline |
| BMI | Body mass index |
| BRFSS | Behavioral Risk Factor Surveillance System |
| BWMP | Behavioral weight management program |
| CAD | Coronary artery disease |
| CBO | Congressional Budget Office |
| CDC | Centers for Disease Control and Prevention |
| CDMO | Contract development and manufacturing organization |
| CI | Confidence interval |
| CKD | Chronic kidney disease |
| Cmax | Maximum plasma concentration |
| CMC | Chemistry, manufacturing, and controls |
| CMS | Centers for Medicare & Medicaid Services |
| COPD | Chronic obstructive pulmonary disease |
| CTC | Common Terminology Criteria |
| CV | Cardiovascular |
| CVD | Cardiovascular disease |
| CYP3A4 | Cytochrome P450 3A4 |
| DLRT | Dose Level Review Team |
| DPP-4 | Dipeptidyl peptidase 4 |
| DSE | Diabetes Support and Education |
| ECO | European Congress on Obesity |
| eGFR | Estimated glomerular filtration rate |
| EOI | End of intervention |
| EQ-5D | EuroQol 5-dimension questionnaire |
| ESKD | End-stage kidney disease |
| ETD | Estimated treatment difference |
| evLY | Equal value of life year |
| FDA | U.S. Food and Drug Administration |
| FPG | Fasting plasma glucose |
| GDP | Gross domestic product |
| GI | Gastrointestinal |
| GIP | Glucose-dependent insulinotropic polypeptide |
| GLP-1 | Glucagon-like peptide-1 |
| GLP-1 RA | Glucagon-like peptide-1 receptor agonist |
| HBPB | Health benefit price benchmark |
| HbA1c | Glycated hemoglobin (hemoglobin A1c) |
| HDL-C | High-density lipoprotein cholesterol |
| HF | Heart failure |
| HFpEF | Heart failure with preserved ejection fraction |
| HFrEF | Heart failure with reduced ejection fraction |
| HR | Hazard ratio |
| HRQoL | Health-related quality of life |
| hsCRP | High-sensitivity C-reactive protein |
| ICER | Institute for Clinical and Economic Review |
| IFSO | International Federation for the Surgery of Obesity and Metabolic Disorders |
| ILI | Intensive lifestyle intervention |
| iNHB | Incremental net health benefit |
| IRR | Incidence rate ratio |
| ITT | Intention to treat |
| IWQOL-Lite-CT | Impact of Weight on Quality of Life-Lite Clinical Trials Version |
| IWRS | Interactive Web Response System |
| KFF | Kaiser Family Foundation |
| LDL-C | Low-density lipoprotein cholesterol |
| LIS | Low-income subsidy |
| LS | Least squares |
| MACE | Major adverse cardiovascular events |
| MAD | Multiple ascending dose |
| MASH | Metabolic dysfunction-associated steatohepatitis |
| MASLD | Metabolic dysfunction-associated steatotic liver disease |
| MBE | Model-based estimate |
| MBS | Metabolic and bariatric surgery |
| MCS | Mental component summary |
| MEN2 | Multiple endocrine neoplasia syndrome type 2 |
| MEPS | Medical Expenditure Panel Survey |
| MetS | Metabolic syndrome |
| MIPS | Merit-based Incentive Payment System |
| mITT | Modified intent-to-treat |
| MMRM | Mixed model for repeated measures |
| MRI-PDFF | Magnetic resonance imaging proton density fat fraction |
| MTC | Medullary thyroid carcinoma |
| MTD | Maximum tolerated dose |
| MVP | MIPS Value Pathway |
| MWPC | Meaningful within-person change |
| NADAC | National Average Drug Acquisition Cost |
| NAFLD | Nonalcoholic fatty liver disease |
| NASH | Nonalcoholic steatohepatitis |
| NCHS | National Center for Health Statistics |
| NDA | New drug application |
| NHANES | National Health and Nutrition Examination Survey |
| NTS | Nucleus tractus solitarius |
| NYHA | New York Heart Association |
| OA | Osteoarthritis |
| OAO | Overweight and obesity |
| OMA | Obesity Medicine Association |
| OR | Odds ratio |
| OSA | Obstructive sleep apnea |
| PAF | Population attributable fraction |
| PBM | Pharmacy benefit manager |
| PCS | Physical component summary |
| PD | Pharmacodynamics |
| PDC | Proportion of days covered |
| PK | Pharmacokinetics |
| PO | By mouth (oral) |
| QALY | Quality-adjusted life year |
| QD | Once daily |
| QM | Once monthly |
| QOW | Once every other week |
| QW | Once weekly |
| RCT | Randomized controlled trial |
| REMS | Risk Evaluation and Mitigation Strategy |
| SAD | Single ascending dose |
| SAE | Serious adverse event |
| SBP | Systolic blood pressure |
| SC | Subcutaneous |
| SD | Standard deviation |
| SE | Standard error |
| SF-12 | 12-Item Short Form Health Survey |
| SF-36 | 36-Item Short Form Health Survey |
| SRC | Safety Review Committee |
| T1/2 | Elimination half-life |
| T2D | Type 2 diabetes |
| T2DM | Type 2 diabetes mellitus |
| TEAE | Treatment-emergent adverse event |
| TESAE | Treatment-emergent serious adverse event |
| Tmax | Time to maximum plasma concentration |
| TOS | The Obesity Society |
| TrOOP | True out-of-pocket |
| ULN | Upper limit of normal |
| USPSTF | U.S. Preventive Services Task Force |
| WAC | Wholesale acquisition cost |
| WC | Waist circumference |
| WHO | World Health Organization |
| WMM | Weight management medication |